PHB1 and non-small cell lung carcinoma: Meanwhile, in vivo PHB1-targeted experiments based on immunocompromised mice bearing NCI-H460 (human NSCLC) tumor xenograft demonstrated that the hybrids NPs treatment resulted in the significant suppression of tumor growth, and the average tumor weight in the NP (siPHB1) group was decreased by about 70% while other groups had no obvious decrease in tumor weight.